Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been the most significant addition to the armoury for the treatment of ovarian cancer since the introduction of platinum therapy in the 1970s and represent a paradigm shift in the way cancers may be treated. This evidence concerns the gene PARP1 and ovarian carcinoma.